# Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT03397394** · PHASE2 · TERMINATED · sponsor: **pharmaand GmbH** · enrollment: 97 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Renal Pelvis Carcinoma
- Ureter Carcinoma
- Urinary Bladder Carcinoma
- Urethra Carcinoma
- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03397394
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-01
- **Primary completion:** 2019-12-12
- **Final completion:** 2020-01-15
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment.
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03397394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03397394, "Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03397394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*